Evaluating health-related quality-of-life outcomes in patients with congestive heart failure: A review of recent randomised controlled trials

PharmacoEconomics

Volumn 15, Issue 1, 1999, Pages 19-46

  Leidy, Nancy K ^a   Rentz, Anne M ^a   Zyczynski, Teresa M ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Astra Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CARVEDILOL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; ENOXIMONE; FELODIPINE; FLOSEQUINAN; HYDRALAZINE; IBOPAMINE; ISOSORBIDE DINITRATE; METOPROLOL; PIPERANOMETOZINE; PLACEBO; PROSTACYCLIN; RAMIPRIL; URAPIDIL; XAMOTEROL;

CLINICAL FEATURE; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DRUG COST; EXERCISE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; TREATMENT OUTCOME; WELLBEING;

HEART FAILURE, CONGESTIVE; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0032909238     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915010-00003     Document Type: Review

References (102)

1. 1. Cohn JN. The management of chronic heart failure. N Engl J Med 1996; 335 (7): 490-8
2. 2. Andrews F, Withey S. Developing measures of perceived life quality: results from several national surveys. Soc Indic Res 1974; 1: 1-26
3. 3. Dupuy HJ. The psychological general well-being (PGWB) index. In: Wenger NK, Mattson ME, Furberg CD. editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq, 1984: 170-84
4. 4. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27 (3 Suppl.): S217-32
5. 5. Gorkin L, Norvell NK, Rosen RC, et al. Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) trial quality-of-life substudy. Am J Cardiol 1993; 71 (12): 1069-73
6. 6. Rogers WJ, Johnstone DE, Yusuf S, et al. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. J Am Coll Cardiol 1994; 23 (2): 393-400
7. 7. Rector TS, Johnson G, Dunkman WB, The V-HeFT VA Cooperative Studies Group, et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life: Circulation 1993; 87 (6 Suppl.): VI71-7
8. 8. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation 1997; 96 (3): 856-63
9. 9. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94 (11): 2807-16
10. 10. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997; 3 (3): 173-9
11. 11. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94 (11): 2800-6
12. 12. Guyatt GH, Sullivan MJJ, Fallen E, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988; 61: 371-5
13. 13. Guyatt GH, Nogradi S, Halcrow S, et al. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989; 4: 101-7
14. 14. Guyatt GH. Measurement of health-related quality of life in heart failure. J Am Coll Cardiol 1993; 22 (4 Suppl. A): 185A-91A
15. 15. Wiklund I, Lindvall K, Swedberg K, et al. Self-assessment of quality of life in severe heart failure. Scand J Psychol 1987; 28: 220-5
16. 16. de Vries RJ, Quere M, Lok DJ, et al. Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure. Am J Cardiol 1995; 76 (17): 1253-8
17. 17. Sasayama S, Asanoi H, Ishizaka S, et al. Evaluation of functional capacity of patients with congestive heart failure. In: Yasuda H, Morgan HE, editors. New aspect in the treatment of failing heart. New York: Springer, 1992: 113-7
18. 18. McNair D, Lorr M, Droppleman L. POMS: profile of mood states. San Diego (CA): EdITS/Educational and Industrial Testing Service, 1992
19. 19. Jenkins CD, Stanton BA, Savageau JA, et al. Coronary artery bypass surgery; physical, psychological, social and economic outcomes six months later. JAMA 1983; 250: 782-8
20. 20. Stewart AL, Ware JE, Sherbourne CD, et al. Psychological distress/well-being and cognitive functioning measures. In: Stewart AL, Ware JE, editors. Measuring functioning and well-being. Durham (NC): Duke University, 1992: 102-42
21. 21. Kaplan RM, Atkins CJ, Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J Chronic Dis 1984; 37 (2): 85-95
22. 22. Kaplan RM, Anderson JP, Wu AW, et al. The quality of well-being scale: applications in AIDS, cystic fibrosis, and arthritis. Med Care 1989; 27 Suppl. 3: S27-43
23. 23. Ganiats TG, Palinkas LA. Kaplan RM. Comparison of quality of well-being scale and functional status index in patients with atrial fibrillation. Med Care 1992; 30 (10): 958-64
24. 24. Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Oper Res 1982; 30: 1043-69
25. 25. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions: health utilities index. Pharmacoeconomics 1995; 7: 503-20
26. 26. EuroQoL Group. EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
27. 27. Ekeberg O, Klemsdal TO. Kjeldsen SE. Quality of life on enalapril after acute myocardial infarction. Eur Heart J 1994; 15 (8): 1135-9
28. 28. Weintraub WS, Mauldin PD, Becker E, et al. A comparison of the costs and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease: results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation 1995; 92: 2831-40
29. 29. Boden WE, Ziesche S, Carson PE, V-HeFT investigators, et al. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. Am J Cardiol 1996; 77: 1078-82
30. 30. Sasayama S, Asanoi H, Kihara Y, et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 1994; 9 (3): 113-20
31. 31. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134 (1): 44-54
32. 32. Just H, Drexler H, Taylor SH, The Captopril and Digoxin Study (CADS) Group, et al. Captopril versus digoxin in patients with coronary artery disease and mild heart failure: a prospective, double-blind, placebo-controlled multicenter study. Herz 1993; 18 Suppl. 1: 436-43
33. 33. Kostis JB, Rosen RC, Cosgrove NM, et al. Nonpharmacologic therapy improves functional and emotional status in congestive heart failure. Chest 1994; 106: 996-1001
34. 34. Naughton MT, Liu PP, Benard DC, et al. Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway pressure. Am J Respir Crit Care Med 1995; 151 (1): 92-7
35. 35. OPC-8212 Multicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther 1990; 4 (2): 419-26
36. 36. Cowley AJ, Skene AM, Enoximone Investigators. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J 1994; 72 (3): 226-30
37. 37. Koch M, Douard J, Broustet J-P. The benefit of graded physical exercise in chronic heart failure. Chest 1992; 191 (5 Suppl.): 231S-5S
38. 38. Barabino A, Galbariggi G, Pizzorni C, et al. Comparative effects of long-term therapy with captopril and obopamine in chronic congestive heart failure in old patients. Cardiology 1991; 78: 243-56
39. 39. Rucinska EJ. Enalapril in the treatment of congestive heart failure: effects on signs, symptoms and mortality. Acta Cardiol 1991; 46 (2): 231-46
40. 40. Gundersen T, Wiklund I, Swedberg K, Ramipril Study Group, et al. Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Cardiovasc Drugs Ther 1995; 9 (4): 589-94
41. 41. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Circulation 1993; 88 (2): 492-501
42. 42. Kubo SH, Gollub S, Bourge R, The Pimobendan Multicenter Research Group, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation 1992; 85 (3): 942-9
43. 43. Wiklund I, Waagstein F, Swedberg K, et al. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Cardiovasc Drugs Ther 1996; 10: 361-8
44. 44. Wiklund I, Swedberg K. Some methodological problems in analyzing quality of life data in severe congestive heart failure patients. Clin Res Pharmacoepidemiol 1991; 5 (3): 265-73
45. 45. Acanfora D, Lanzillo T, Papa A, et al. Congestive heart failure in elderly patients: controlled study of delapril versus captopril. Am J Cardiol 1995; 75 (18): 37F-43F
46. 46. Feldman AM, Baughman KL, Lee WK, et al. Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1991;68: 1203-10
47. 47. Feldman AM, Bristow MR, Parmley WW, Vesnarinone Study Group, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329 (3): 149-55
48. 48. DiBianco R, Parker JO, Chakko S, et al. Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study. Am Heart J 1991; 121 (1 Pt 2): 372-80
49. 49. Tyni-Lenne R, Gordon A, Sylven C. Improved quality of life in chronic heart failure patients following local endurance training with leg muscles. J Card Fail 1996; 2 (2): 111-7
50. 50. Kavanagh T, Myers MG, Baigrie RS, et al. Quality of life and cardiorespiratory function in chronic heart failure: effects of 12 months' aerobic training. Heart 1996; 76: 42-9
51. 51. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333 (18): 1190-5
52. 52. Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? N Engl J Med 1996; 334 (22): 1441-7
53. 53. Schulman KA, Buxton MJ, Glick H, et al. Prospective economic evaluation of the first study. Annu Meet Int Soc Technol Assess Health Care 1995; 11: Abstract no. 2
54. 54. Blackwood R, Mayou RA, Garnham JC, et al. Exercise capacity and quality of life in the treatment of heart failure. Clin Pharmacol Ther 1990; 48 (3): 325-32
55. 55. Hawthorne MH, Hixon ME. Functional status, mood disturbance and quality of life in patients with heart failure. Prog Cardiovasc Nurs 1994; 9 (1): 22-32
56. 56. Northridge DB, Rose E, Raftery ED, et al. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure. Eur Heart J 1993; 14 (3): 403-9
57. 57. Dorszewski A, Göhmann E, Dorszewski B, et al. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. J Card Fail 1997; 3 (2): 91-6
58. 58. Tyni-Lenne R, Gordon A, Jansson E, et al. Skeletal muscle endurance training improves peripheral oxidative capacity, exercise tolerance, and health-related quality of life in women with chronic congestive heart failure secondary to either ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 80: 1025-9
59. 59. Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 1998; 98: 953-60
60. 60. Baligadoo SJ, Subratty H, Manraz M, et al. Effects of enoximone on quality of life. Int J Cardiol 1990; 28 Suppl. 1: S29-32
61. 61. Dubourg O, Delorme G, Hardy A, et al. Placebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatment. Int J Cardiol 1990; 28 Suppl. 1: S33-42
62. 62. The Italian Xamoterol Multicenter Research Group. Comparative effects of xamoterol and digoxin in patients with mild to moderate heart failure. Eur Heart J 1990; 11 Suppl. A: 50-1
63. 63. Parker JO, The Ibopamine Study Group. The effects of oral ibopamine in patients with mild heart failure: a double blind placebo controlled comparison to furosemide. Int J Cardiol 1993; 40 (3): 221-7
64. 64. McNair DM, Lorr M, Dropplemann LF. Manual of the profile of moods states. San Diego (CA): Educational and Industrial Testing Service, 1971
65. 65. Mayou R, Bryant B. Quality of life after coronary artery surgery. Q J Med 1987; 239: 239-48
66. 66. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. Arthritis Rheum 1980; 23: 146-52
67. 67. Bergner M. The sickness impact profile (SIP). In: Wenger NK, Mattson ME, Furberg CD, et al., editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York (NY): Le Jacq. 1984: 152-9
68. 68. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987; 3: 198-209
69. 69. Hunt SM, McKenna SP. The Nottingham health profile user manual. Manchester: Galen Research, 1991
70. 70. Vigholt-Sorensen E, Faergeman O, Snow HM. Effects of xamoterol, a beta-adrenoceptor partial agonist, in patients with ischemic dysfunction of the left ventricle. Br Heart J 1989; 62: 335-41
71. 71. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 919-23
72. 72. Sparrow J, Parameshwar J, Poole-Wilson PA. Assessment of functional capacity in chronic heart failure: time-limited exercise on a self-powered treadmill. Br Heart J 1996; 71: 391-4
73. 73. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992; 124: 1017-25
74. 74. Rosser R, Sintonen H. The EuroQol quality of life project. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990s. Dordrecht: Kluwer Academic Publishers, 1993: 197-9
75. 75. Hunt SM, McKenna SP, McEwen J, et al. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med 1981; 15: 221-9
76. 76. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure Questionnaire as a measure of therapeutic response: effects of enalapril and placebo. Am J Cardiol 1993; 71: 1106-7
77. 77. McNair DM, Lorr M. An analysis of moods and neurotics. J Abnorm Soc Psychol 1964; 69: 620-7
78. 78. Mishel MH. The Mishel uncertainty in illness manual. Chapel Hill (NC): University of North Carolina, 1990
79. 79. Ferrans CE, Powers MJ. Psychometric assessment of the quality of life index. Res Nurs Health 1992; 15: 29-38
80. 80. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71
81. 81. Bergner M, Bobbitt RA, Carter W, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 19: 787-806
82. 82. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36). II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-63
83. 83. Ware JE Jr, Snyder MK, Wright WR, et al. Defining and measuring patient satisfaction with medical care. Eval Program Plann 1983; 6: 247-63
84. 84. Goldman L, Hashimoto B, Cook F, et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981; 64: 1227-34
85. 85. Dracup K, Walden JA, Stevenson LW, et al. Quality of life in patients with advanced heart failure. J Heart Lung Transplant 1992; 11 (2 Pt 1): 273-9
86. 86. Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. Int J Cardiol 1995; 49 (3): 191-9
87. 87. Antonovsky A. The structure and properties of the sense of coherence scale. Soc Sci Med 1993; 36: 725-33
88. 88. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I: conceptual framework and item selection. Med Care 1992; 30: 473-83
89. 89. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 32: 50-5
90. 90. Buxton M, Acheson RM, Caine N, et al. Costs and benefits of the heart transplant programmes at Harefield and Papworth Hospitals, London. London: HMSO, 1985
91. 91. Bulpitt CJ, Fletcher AE. Effect of treatment on the quality of life in hypertension and congestive heart failure. Cardiology 1988; 75 Suppl. 1: 53-60
92. 92. Fletcher AE, Hunt BM, Bulpitt CJ. Evaluation of quality of life in clinical trials of cardiovascular disease. J Chronic Dis 1987; 40 (6): 557-69
93. 93. Wallwork J, Caine N. A comparison of the quality of life of cardiac transplant patients and coronary artery bypass graft patients before and after surgery. Qual Life Cardiovasc Care 1985; 1: 317-31
94. 94. Bulpitt CJ, Fletcher AE. Measurement of the quality of life in congestive heart failure: influence of drug therapy. Cardiovasc Drugs Ther 1988; 2 Suppl. 1: 419-24
95. 95. Fletcher AE, Bulpitt CJ. Measurement of quality of life in clinical trials of therapy. Cardiology 1988; 75 Suppl. 1: 41-52
96. 96. Tandon PK, Stander H, Schwartz RP. Analysis of quality of life data from a randomized, placebo-controlled heart-failure trial. J Clin Epidemiol 1989; 42: 955-62
97. 97. Vermeer F, Simoons ML, de Zwaan C, et al. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase: twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands. BMJ 1988; 59 (5): 527-34
98. 98. Wong JB, Sonnenberg FA, Salem DN, et al. Myocardial revascularization for chronic stable angina. Ann Intern Med 1990; 113: 852-71
99. 99. Leidy, NK. Using functional status to assess treatment outcomes. Chest 1994; 106 (6): 1645-6
100. 100. Kinney MR, Burfitt SN, Stullenbarger E, et al. Quality of life in cardiac patient research: a meta-analysis. Nurs Res 1996; 45: 173-80
101. 101. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol 1989; 64 (10): 651-4
102. 102. Karmilovich SE. Burden and stress associated with spousal caregiving for individuals with heart failure. Prog Cardiovasc Nurs 1994; 9 (1): 33-8